ArticleExperimental hematology & oncology2025

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Ines Zugasti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.